Skip to search formSkip to main contentSkip to account menu

lenvatinib 18 MG Daily Dose 30 Day Supply Pack

Known as: LENVATINIB 10MG X 30/4MG X 60 (18MG) DAILY PKT, LENVATINIB 10MG X 5/4MG X 10 (18MG) DAILY PKT [VA Product], LENVATINIB 10MGX5/4MGX10(18MG) DAILY PKT 
National Institutes of Health

Related topics

Related topics

3 relations
PackReceptor Tyrosine Kinase Inhibitors [MoA]lenvatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis
2019
2019
Mo1454 – Lenvatinib for Patients with Advanced Hepatocellular Carcinoma Refractory to Transcathetal Chemoembolization
2019
2019
A retrospective analysis of efficacy of systemic therapy in metastatic thyroid cancer
Amac: Tiroid kanserleri, endokrin kanserleri icerisinde en sik gorulen kanserdir. Metastatik tiroid kanserlerinin sistemik… 
2018
2018
Zwei Fälle perforierender Dermatosen bei Therapie mit Multikinase‐Inhibitoren, einer davon assoziiert mit Lenvatinib
2017
2017
Abstract 1805: Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
Hepatocellular carcinoma (HCC) is a one of the leading causes of cancer death worldwide; however systemic therapeutic option for… 
2016
2016
Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth
Lenvatinib mesilate (lenvatinib) is an orally available inhibitor for multiple receptor tyrosine kinases (RTKs) that selectively… 
2015
2015
Individualisierte Therapie des fortgeschrittenen Schilddrüsenkarzinoms
ZusammenfassungHintergrundDas zunehmende Verständnis der komplexen molekularen Pathogenese mit der Identifizierung molekularer… 
2014
2014
NSCLC: Längeres Überleben bei guter Lebensqualität im Fokus
— Beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) steht nicht nur die Lebensverlängerung im Fokus, sondern auch… 
2014
2014
新規分子標的薬 lenvatinib (肝細胞癌治療の最前線)
2014
2014
Radiojod-refraktäres Schilddrüsenkarzinom: Längeres PFS unter Lenvatinib
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)